New Combination Injectable Drugs of Insulin and a Incretin Mimetic (GLP-1 Agonist) specific for use in management of Type 2 Diabetes Mellitus, approved for use in the United States.
Soliqua™ 100/33 (Sanofi), a combination of U100 insulin glargine and lixisenatide (GLP-1 Agonist), will be available in retail pharmacies in the United States as of January 2017.
Xultophy™ 100/3.6 (Novo Nordisk), a combination of U100 insulin degludec and liraglutide (GLP-1 Agonist), will not be available until some time in the first half of 2017, the date has yet to be established.
Note: These drugs are actually a new drug category specific for use in Type 2 Diabetes Mellitus. You will find this new drug category included in the drug tables of the new diabetes course being released summer of 2017.